User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

Interactions with Platform & by Email *

INTERACTIONS

Unique # Participated *

PARTICIPANTS

Responses Validated *

VALIDATIONS

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definition and Scope of Study.....I-3
  
   Safety Concerns and Generics Characterize the Market.....II-1
“Perfect” Treatment Option Continues to Evade Insomnia Therapeutics Arena.....II-1
1$100
   A Market Characterized by Weak Pipeline.....II-2
Market Outlook.....II-2
Sleep Disorders – Not Confined to Elderly Alone.....II-2
US Leads the Global Market for Sleeping Pills.....II-2
1$100
   Table 1: US Prevalence of Chronic Insomnia by Type: 2008 (includes corresponding Graph/Chart).....II-3
Studies Cast Doubt On the Efficacy of Sleeping Pills.....II-3
1$300
   Market Categorization.....II-4
Table 2: Select Benzodiazepines and Non-Benzodiazepines Worldwide.....II-4
1$300
   Benzodiazepines Loose Sheen Due to Associated Side Effects.....II-5
‘Z’ Drugs Outshine Benzodiazepines with Lesser Adverse Effects...II-5
Table 3: Sales of Select Leading Sleeping Pills Worldwide.....II-5
1$300
   Melatonin Receptor Agonist Hypnotic.....II-6
Rozerem – The Only Drug without the Risk of Dependency.....II-6
1$100
   Zolpidem (Sanofi-Aventis/Various).....II-7
Ambien CR (Sanofi-Aventis).....II-7
Lunesta (Sepracor).....II-7
1$100
   Intermezzo (Transcept).....II-8
Sonata (King Pharmaceuticals).....II-8
Imovane (Sanofi-Aventis).....II-8
1$100
   Sleep Disorder Pipeline Analysis.....II-91$100
   Insomnia – A Review.....II-10
Impact on Day-to-day Life.....II-10
Insomnia: An Under-Diagnosed Disease.....II-10
1$100
   Middle-Of-The-Night Insomnia.....II-11
What are Sleeping Pills?.....II-11
When it Should be Taken?.....II-11
Side Effects – A Key Concern.....II-11
1$100
   Natural Treatment of Insomnia.....II-12
Eye Cells – A New Potential Target for Sleeping Pills.....II-12
1$100
   Regional Market Perspective.....II-13
6a. THE UNITED STATES.....II-13
Economic Woes Drive Usage of Sleeping Pills.....II-13
Table 4: Sleeping Pills Prescription Volume in the US: 2006-2008 (includes corresponding Graph/Chart).....II-13
1$300
   Table 5: Sleeping Pills Prescription Volume in the US by Drug: 2006-2008 (In Million) (includes corresponding Graph/Chart).....II-14
Dangerous Signs for Americans.....II-14
OTC Sleeping Aids Market Review.....II-14
1$300
   Table 6: Leading OTC Sleeping Aid Tablets in the US (2008): Percentage Breakdown of Value Sales for Simply Sleep, Unisom SleepGels, Unisom SleepTabs, Sleep MD, Sominex, Midnite, Breathe Right, Sleepinal, Private Label Brands and Others (includes corresponding Graph/Chart).....II-15

Table 7: Leading OTC Sleeping Aid Tablets in the US (2008): Percentage Breakdown of Volume Sales for Simply Sleep, Unisom SleepGels, Sominex, Unisom SleepTabs, Sleep MD, Midnite, Sleepinal, Breathe Right, Private Labels and Others (includes corresponding Graph/Chart).....II-15
1$300
   Table 8: Leading OTC Sleeping Aid Liquid Drugs in the US Drug Stores (2007): Percentage Breakdown of Value Sales for Breathe Right, Snorestop, Bach Rescue Sleep, Nutramist Sleep Now, Nutranetics Liquid Sleep and Others (includes corresponding Graph/Chart).....II-16

Table 9: Leading OTC Sleeping Pills in US Drug Stores (2007): Percentage Breakdown of Value Sales for Simply Sleep, Unisom Sleepgels, Sleep MD, Unisom, Sominex and Others (includes corresponding Graph/Chart).....II-16

Table 10: Leading OTC Sleeping Pills in US Drug Stores (2007): Percentage Breakdown of Volume Sales for Simply Sleep, Unisom Sleepgels, Sominex, Unisom, Sleep MD and Others (includes corresponding Graph/Chart).....II-16
1$300
   6b. EUROPE.....II-17
Europe: A Major Market for Sleeping Pills.....II-17
Table 11: European Prevalence of Chronic Insomnia by Type: 2008 (includes corresponding Graph/Chart).....II-17
1$300
   Table 12: Sleeping Disorders in Europe (2008): Prevalence Rate by Age Group for Select European Countries - France, Germany, Italy, UK (includes corresponding Graph/Chart).....II-18

Table 13: Sleeping Disorders in Europe (2008): Prevalence Rate by Gender for Select European Countries - France, Germany, Italy, UK (includes corresponding Graph/Chart).....II-18
1$300
   6c. JAPAN.....II-19
Illegal Sales of Sleeping Pills Rampant in Japan.....II-19
1$100
   6d. TAIWAN.....II-20
Sleeping Pills Sales Continue to Soar.....II-20
1$100
   Somaxon Pharma Receives US FDA Approval for Silenor.....II-21
Transcept Pharmaceuticals Merges with Novacea.....II-21
Sepracor Files Lawsuits Against ANDA Filers for Eszopiclone.....II-21
1$100
   Dainippon Sumitomo Takes Over Sepracor.....II-22
FDA Puts Two Pediatric Studies of Lunesta on Hold.....II-22
Transcept Pharmaceuticals Signs Deal with Purdue Pharmaceutical Products.....II-22
Sepracor Receives Approval for Lunesta Oral Tablet.....II-22
FDA Approves Mylan’s ANDA for Zaleplon Capsules.....II-22
1$100
   GlaxoSmithKline Signs Agreement with Actelion.....II-23
Lundbeck Launches Circadin® in Germany for Insomnia.....II-23
Lundbeck Launches Circadin in the UK.....II-23
Transcept Completes Phase III Study of Intermezzo, Files NDA.....II-23
1$100
   Evotec Scouts for Partners to Develop EVT 201.....II-24
Aurobindo Pharma Receives FDA Approval for Zaleplon.....II-24
Australia’s TGA Orders Boxed Warnings for Stilnox.....II-24
Sepracor Obtains Positive Opinion for Approval of Lunivia from CHMP.....II-24
1$100
   Caraco Obtains FDA Approval for Generic Zolpidem.....II-25
FDA Approves ANDA of Dr. Reddy's Laboratories for Zolpidem Tartrate.....II-25
Ranbaxy Obtains FDA Clearance to Market Generic Ambien®.....II-25
Neurocrine Obtains Second Approvable Letter from FDA for Indiplon Capsules.....II-25
1$100
   Roxane Launches Zolpidem Tartrate Tablets.....II-261$100
   Actelion Pharmaceuticals Ltd. (Switzerland).....II-27
Abbott India Limited (India).....II-27
Apotex Inc. (Canada).....II-27
Aurobindo Pharma Limited (India).....II-27
1$100
   Caraco Pharmaceutical Laboratories, Ltd. (US).....II-28
Dr. Reddy’s Laboratories Limited (India).....II-28
H. Lundbeck A/S (Denmark).....II-28
King Pharmaceuticals, Inc. (US).....II-28
1$100
   Neurocrine Biosciences (US).....II-29
Ranbaxy Laboratories Limited (India).....II-29
Roxane Laboratories, Inc. (US).....II-29
Sepracor, Inc. (USA).....II-29
1$100
   Sanofi-aventis (France).....II-301$100
   Somaxon Pharmaceuticals, Inc. (US).....II-31
Synthon BV (The Netherlands).....II-31
Takeda Pharmaceutical Company Limited (Japan).....II-31
Transcept Pharmaceuticals, Inc. (US).....II-31
1$100
   Table 14: World Recent Past, Current and Future Analysis for Sleeping Pills by Geographic Region - US, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-321$300
   Table 15: World Historic Review for Sleeping Pills by Geographic Region - US, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-331$300
   Table 16: World 13-Year Perspective for Sleeping Pills by Geographic Region - Percentage Breakdown of Dollar Sales for US, and Rest of World Markets for Years 2003, 2009 and 2015 (includes corresponding Graph/Chart).....II-341$300
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com